The data also show that the inhibition of ERK1/2 phosphorylation by single therapy and its elevated suppression under combined conditions indicate a potential effect of the treatments on the proliferation of hepatocellular carcinoma cells. The gene discussed is MAPK3; the disease is hepatocellular carcinoma.